HomePhase I data of RXDX-101, a kinase inhibitor discovered at Nerviano Medical Sciences, in patients with advanced solid tumors with relevant molecular alterations to be disclosed at 2014 ASCO

Phase I data of RXDX-101, a kinase inhibitor discovered at Nerviano Medical Sciences, in patients with advanced solid tumors with relevant molecular alterations to be disclosed at 2014 ASCO

Nerviano, 14.05.2014

Nerviano Medical Sciences has discovered RXDX-101, an oral pan-trk, ROS1, and ALK inhibitor, recently outlicenced to Ignyta, Inc, San Diego, CA.
Phase I results of RXDX-101 in patients with advanced solid tumors with relevant molecular alterations will be disclosed at the 2014 American Society of Clinical Oncology (ASCO) annual meeting.

Presentation title: Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.
Authors: De Braud, F et al

Meeting: 2014 ASCO Annual Meeting
Abstract No: 2502

Sub-category: Cytotoxic and Other Novel Agents
Category: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics

Type: Oral Abstract Session
Time: Saturday May 31, 1:15 PM to 4:15 PM
Location: E Hall D2